A second liver biopsy was performed, and subsequent pathology showed “(liver) poorly differentiated carcinoma, and lung adenocarcinoma metastasis was considered in combination with immunohistochemistry analysis.” Tissue biopsy was subjected to a second round of genetic testing, which indicated “BRAFV600E 14.79%, EML 4-ALK fusion 14.47%” (Fig. 5). Here, ALK is linked to lung adenocarcinoma.